During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

【导读】激素受体阳性（HR+）/人表皮生长因子受体2阴性（HER2-）乳腺癌是最常见的乳腺癌类型，持续复发仍是一个重要的临床问题。目前针对HR+/HER2-乳腺癌患者的复发预测模型仍存在局限性。整合多维数据是预测复发的一种有前途的替代方法。2025年 ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Unraveling the role of interferon-stimulated neutrophils: A promising biomarker for immunotherapy efficacy and prognosis in gastric adenocarcinoma. Outcomes of patients by HER2 heterogeneity and gene ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...